Asunto(s)
Aspirina/efectos adversos , Hematemesis/inducido químicamente , Heparina/efectos adversos , Infarto del Miocardio/tratamiento farmacológico , Estreptoquinasa/efectos adversos , Terapia Trombolítica/efectos adversos , Aspirina/administración & dosificación , Fibrinolíticos/administración & dosificación , Fibrinolíticos/efectos adversos , Estudios de Seguimiento , Heparina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/diagnóstico , Estreptoquinasa/administración & dosificaciónRESUMEN
Among various hepatic manifestations of Wilson's disease, fulminant hepatic failure is the most uncommon entity and requires a detailed clinicopathological analysis for correct diagnosis. Left unrecognized and without proper therapy, in time the disease rapidly progresses to death. We describe a 24-year-old woman who died within five weeks of the onset of Wilson's disease, which presented with a dramatic course. Discriminating features of the disease are discussed with regard to the literature.
Asunto(s)
Encefalopatía Hepática/diagnóstico , Encefalopatía Hepática/etiología , Hepatitis/complicaciones , Degeneración Hepatolenticular/complicaciones , Adulto , Ceruloplasmina/análisis , Cobre/sangre , Progresión de la Enfermedad , Resultado Fatal , Femenino , Encefalopatía Hepática/patología , Hepatitis/patología , Degeneración Hepatolenticular/patología , Humanos , Túbulos Renales Proximales/patologíaRESUMEN
To determine the prevalence of HCV genotypes in Slovenia, 203 subjects infected with hepatitis C virus (HCV) were studied using the Inno-Lipa HCV II assay (Innogenetics, Belgium). Of 21 patients infected by blood transfusion 19% had HCV subtype 1a, 81% had subtype 1b, and none of them was infected with genotype 3. In chronic hepatitis C patients infected by unknown cause subtype 1b was the most prevalent (54.4%), followed by subtype 1a (24.6%), genotype 3 (15.8%) and genotype 2 (5.2%). Genotype 3 (45.9%) and subtype 1a (43.2%) predominated among 74 intravenous drug users. In 37 haemodialysis patients genotypes 1 and 2 were almost equally frequent (40.5% and 37.8%, respectively), followed by genotype 3 (21.6%). Significant differences in HCV genotype distribution among distinct epidemiological groups observed in Slovenia indicate a close relationship between certain HCV genotypes and particular routes of viral transmission.